{"classes":[{"categories":[{"measurements":[{"comment":"Could not be estimated due to the low number of events","groupId":"OG000","lowerLimit":"28.4","upperLimit":"NA","value":"45.6"},{"comment":"Could not be estimated due to the low number of events","groupId":"OG001","lowerLimit":"33.4","upperLimit":"NA","value":"NA"},{"comment":"Could not be estimated due to the low number of events","groupId":"OG002","lowerLimit":"27.1","upperLimit":"NA","value":"37.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"59"},{"groupId":"OG002","value":"70"}],"units":"Participants"}],"description":"Overall Survival is defined as the time from the start of study treatment to date of death due to any cause.\n\nPatients who were alive or lost to follow-up as of the data analysis cut-off date for the final OS analysis were censored at the date the patient was last known to be alive. Median OS was estimated using the Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants previously treated with bortezomib received carfilzomib 20 mg/m² intravenous (IV) injection on Days 1, 2, 8, 9, 15, and 16, in 28-day treatment cycles for a maximum of 12 cycles.","id":"OG000","title":"Part 1: Carfilzomib 20 mg/m²"},{"description":"Participants not previously treated with bortezomib received carfilzomib 20 mg/m² IV injection on Days 1, 2, 8, 9, 15, and 16, in 28-day treatment cycles for a maximum of 12 cycles.","id":"OG001","title":"Part 2: Carfilzomib 20 mg/m²"},{"description":"Participants not previously treated with bortezomib received carfilzomib 20 mg/m² IV on Days 1, 2, 8, 9, 15, and 16 of Cycle 1. If all doses were well-tolerated the dose was escalated to 27 mg/m² IV on Days 1, 2, 8, 9, 15, and 16 for subsequent cycles, for up to 12 cycles.","id":"OG002","title":"Part 2: Carfilzomib 20/27 mg/m²"}],"paramType":"MEDIAN","populationDescription":"Safety Population includes all patients enrolled on study and who received at least 1 dose of carfilzomib.","reportingStatus":"POSTED","timeFrame":"Patients were followed for up to 2 years after study discontinuation. The data cutoff for the analysis is 19 November 2012 for Part 1 and 07 January 2013 for Part 2. Median follow-up time was 19.1 months for Part 1 and 35.9 months in Part 2.","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}